Chad Landmon, JD

Chad Landmon, JD, is a partner at Axinn, where he chairs the firm’s FDA and intellectual property practice groups. He regularly works with companies developing drugs, biologics, and regenerative medicine and human tissue products. Jonathan Knowles, JD, is an associate at Axinn. At this time, his admission to the New York bar is pending.
The FDA maintained its requirement that all newly licensed biologics include a 4-letter suffix to distinguish each product, and even extended this requirement to interchangeable biosimilars. This provision, among others, has stoked concerns in the biosimilars industry and in many circles concerned about lowering drug costs.
Mar 19, 2019 @01:41 PM

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.